UniQure’s Lousy Timing
Research - UniQure (QURE) announced last Friday the appointment of a new CEO, Dan Soland, replacing long-time executive Jorn Aldag. The timing was atrocious.
PremiumSearch Results for gene therapy
The Fed’s Rate Raise is Finally Behind Us
Research - The Fed announced Wednesday afternoon the first increase to the federal funds rate since 2006, to between 0.25% and 0.5%, and up from near-zero percent for the last seven years.
Premium
At ASH, Bluebird Disappoints (Again) While Bellicum Shines
Research - Just as investors were getting comfortable with bluebird bio’s (BLUE) most recent disappointment, it’s happened again. Today at the American Society of Hematology’s annual meeting, bluebird revealed updated results from HGB-206, the company’s small phase 1/2 study dedicated exclusively to treating Sickle Cell Disease patients with LentiGlobin.
Premium
Well, That Was a Wild Week
Insights - Depending how you were positioned, this last week was one of the most entertaining, educational, and wild of the year. And the sell the news phenomenon … Continue Reading
Read now
Let’s List All of the Events Impacting Sentiment for Equities…
Insights - The NASDAQ Biotech Index (NBI) ended the week on a low note – just 2 percentage points from giving back the entirety of its gains … Continue Reading
Read now
A Mid-September Biotech Update
Research - What a crazy end of summer. Thankfully, today’s the first day of Fall. We’ve got a bunch of updates – insights and administrative – for … Continue Reading
Premium
A September Market Update
Research - Last week was yet another exhausting, anemic few sessions in the markets. One day we're up, and the next we're down - with gaps nonetheless - but a trend is non-existent.
Premium